



<223> Description of Artificial Sequence:Oncostatin M  
CTLA4 (OMCTLA4) Forward Primer

<400> 4  
gaggtgataa agttcacca atgggtgtac tgctcacaca g

41

<210> 5  
<211> 42  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Oncostatin M  
CTLA4 (OMCTLA4) Reverse Primer

<400> 5  
gtggtgtatt ggtctagatc aatcagaatc tggcacggt tc

42

<210> 6  
<211> 1152  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:CTLA4Ig

<400> 6  
atgggtgtac tgctcacaca gaggacgctg ctcaactgg tccttgcact cctgtttcca 60  
agcatggcga gcatggcaat gcacgtggcc cagcctgctg tggactggc cagcagccga 120  
gcacatcgcta gctttgtgt tgtagtatgca tctccaggca aagccactga ggtccgggtg 180  
acagtgcattc ggcaggctga cagccagggtg actgaagtct gtgcggcaac ctacatgatg 240  
ggaaatgagt tgacccctt agatgattcc atctgcacgg gcacctccaa tggaaatcaa 300  
gtgaacacctca ctatccaagg actgagggcc atggacacgg gactctacat ctgcaagggtg 360  
gagctcatgt acccaccggcc atactacctg ggcataaggca acggaaccca gatttatgta 420  
attgatccag aaccgtgccc agattctgtat caggagccca aatcttctga caaaaactcac 480  
acatccccac cgtccccacg acctgaactc ctgggtggat cgtcagtctt cctctcccc 540  
ccaaaaccca aggacacccct catgatctcc cggacccctg aggtcacatg cgtgggtgt 600  
gacgtgagcc acgaagaccc tgaggtcaag ttcaactggt acgtggacgg cgtggagggtg 660  
cataatgccca agacaaagcc gcgggaggag cagtaacaaca gcacgttaccg ggtggtcagc 720  
gtccctcaccc tcctgcacca ggactggctg aatggcaagg agtacaagtg caaggtctcc 780  
aacaaaagccc tcccagcccc catcgagaaa accatctcca aagccaaagg gcagccccga 840  
gaaccacagg tgtacaccct gccccatcc cggatgagc tgaccaagaa ccaggtcagc 900  
ctgacctgcc tggtaaaagg cttctatccc agcgacatcg ccgtggagtg ggagagcaat 960  
gggcagccgg agaacaacta caagaccacg cctccctgc tggactccga cggctccctc 1020  
ttccctctaca gcaagctcac cgtggacaag agcaggtggc agcaggggaa cgtcttctca 1080  
tgctccgtga tgcataggc tctgcacaac cactacacgc agaagagccct ctcctgtct 1140  
ccggtaaat ga 1152

<210> 7  
<211> 383  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: CTLA4Ig

<400> 7

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Gly | Val | Leu | Leu | Thr | Gln | Arg | Thr | Leu | Leu | Ser | Leu | Val | Leu | Ala |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |
| Leu | Leu | Phe | Pro | Ser | Met | Ala | Ser | Met | Ala | Met | His | Val | Ala | Gln | Pro |
|     |     |     |     | 20  |     |     |     | 25  |     |     |     |     | 30  |     |     |
| Ala | Val | Val | Leu | Ala | Ser | Ser | Arg | Gly | Ile | Ala | Ser | Phe | Val | Cys | Glu |
|     |     |     |     | 35  |     |     | 40  |     |     |     | 45  |     |     |     |     |
| Tyr | Ala | Ser | Pro | Gly | Lys | Ala | Thr | Glu | Val | Arg | Val | Thr | Val | Leu | Arg |
|     |     |     |     |     | 50  |     | 55  |     |     | 60  |     |     |     |     |     |
| Gln | Ala | Asp | Ser | Gln | Val | Thr | Glu | Val | Cys | Ala | Ala | Thr | Tyr | Met | Met |
|     |     |     |     | 65  |     | 70  |     |     | 75  |     |     |     | 80  |     |     |
| Gly | Asn | Glu | Leu | Thr | Phe | Leu | Asp | Asp | Ser | Ile | Cys | Thr | Gly | Thr | Ser |
|     |     |     |     | 85  |     |     |     | 90  |     |     |     | 95  |     |     |     |
| Ser | Gly | Asn | Gln | Val | Asn | Leu | Thr | Ile | Gln | Gly | Leu | Arg | Ala | Met | Asp |
|     |     |     |     | 100 |     |     | 105 |     |     |     | 110 |     |     |     |     |
| Thr | Gly | Leu | Tyr | Ile | Cys | Lys | Val | Glu | Leu | Met | Tyr | Pro | Pro | Pro | Tyr |
|     |     |     |     | 115 |     |     | 120 |     |     | 125 |     |     |     |     |     |
| Tyr | Leu | Gly | Ile | Gly | Asn | Gly | Thr | Gln | Ile | Tyr | Val | Ile | Asp | Pro | Glu |
|     |     |     |     | 130 |     |     | 135 |     |     | 140 |     |     |     |     |     |
| Pro | Cys | Pro | Asp | Ser | Asp | Gln | Glu | Pro | Lys | Ser | Ser | Asp | Lys | Thr | His |
|     |     |     |     | 145 |     | 150 |     |     | 155 |     |     |     | 160 |     |     |
| Thr | Ser | Pro | Pro | Ser | Pro | Ala | Pro | Glu | Leu | Leu | Gly | Gly | Ser | Ser | Val |
|     |     |     |     | 165 |     |     |     | 170 |     |     | 175 |     |     |     |     |
| Phe | Leu | Phe | Pro | Pro | Lys | Pro | Lys | Asp | Thr | Leu | Met | Ile | Ser | Arg | Thr |
|     |     |     |     | 180 |     |     | 185 |     |     | 190 |     |     |     |     |     |
| Pro | Glu | Val | Thr | Cys | Val | Val | Val | Asp | Val | Ser | His | Glu | Asp | Pro | Glu |
|     |     |     |     | 195 |     |     | 200 |     |     | 205 |     |     |     |     |     |
| Val | Lys | Phe | Asn | Trp | Tyr | Val | Asp | Gly | Val | Glu | Val | His | Asn | Ala | Lys |
|     |     |     |     | 210 |     |     | 215 |     |     | 220 |     |     |     |     |     |
| Thr | Lys | Pro | Arg | Glu | Glu | Gln | Tyr | Asn | Ser | Thr | Tyr | Arg | Val | Val | Ser |
|     |     |     |     | 225 |     | 230 |     |     | 235 |     |     | 240 |     |     |     |
| Val | Leu | Thr | Val | Leu | His | Gln | Asp | Trp | Leu | Asn | Gly | Lys | Glu | Tyr | Lys |
|     |     |     |     | 245 |     |     |     | 250 |     |     | 255 |     |     |     |     |
| Cys | Lys | Val | Ser | Asn | Lys | Ala | Leu | Pro | Ala | Pro | Ile | Glu | Lys | Thr | Ile |
|     |     |     |     | 260 |     |     | 265 |     |     | 270 |     |     |     |     |     |
| Ser | Lys | Ala | Lys | Gly | Gln | Pro | Arg | Glu | Pro | Gln | Val | Tyr | Thr | Leu | Pro |
|     |     |     |     | 275 |     |     | 280 |     |     | 285 |     |     |     |     |     |

Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu  
290 295 300

Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn  
305 310 315 320

Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser  
325 330 335

Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg  
340 345 350

Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu  
355 360 365

His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys  
370 375 380

<210> 8  
<211> 1152  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:L104EA29YIg

<400> 8  
atgggtgtac tgctcacaca gaggacgctg ctcagtctgg tccttgcact cctgtttcca 60  
agcatggcga gcatggcaat gcacgtggcc cagcctgctg tggtaactggc cagcagccga 120  
gcacatcgcta gctttgtgt tgtagtatgca tctccaggca aataatactga ggtccgggtg 180  
acagtgcctc ggcaggtga cagccagggtg actgaagtct gtgcggcaac ctacatgtatg 240  
ggaaatgagt tgacccctt agatgattcc atctgcacgg gcaccccttcaag tggaaatcaa 300  
gtgaacctca ctatccaagg actgagggcc atggacacgg gactctacat ctgcaagggt 360  
gagctcatgt acccaccgccc atactacgg ggcataaggca acggaaaccca gatttatgt 420  
attgatccag aaccgtgccc agattctgat caggagccca aatcttctgt caaaaactcac 480  
acatccccac cgtcccccagc acctgaactc ctggggggat cgtcagtctt cctcttcccc 540  
ccaaaaccca aggacaccct catgatctcc cggacccctg aggtcacatg cgtgggtgg 600  
gacgtgagcc acgaagaccc tgaggtaag ttcaactgtt acgtggacgg cgtggagggt 660  
cataatgcca agacaaagcc gcggggaggag cagtacaaca gcacgttaccc tgggttcagc 720  
gtcctcaccc tcctgcacca ggactggctg aatggcaagg agtacaagtg caaggtctcc 780  
aacaaaagccc tcccagcccc catcgagaaa accatctcca aagccaaagg gcagccccga 840  
gaaccacagg tgtacaccct gccccccatcc cgggatgagc tgaccaagaa ccaggtcagc 900  
ctgacccgtcc tggtaaaagg cttctatccc agcgacatcg ccgtggagtg ggagagcaat 960  
gggcagccgg agaacaacta caagaccacg cctccctgtc tgactccga cggctccccc 1020  
ttcccttaca gcaagctcac cgtggacaag agcagggtgc agcaggggaa cgtcttctca 1080  
tgctccgtga tgcatacggtc tctgcacaaac cactacacgc agaagagcct ctccctgtct 1140  
ccgggttaat ga 1152

<210> 9  
<211> 383  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:L104EA29YIg

<400> 9

Met Gly Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val Leu Ala  
1 5 10 15

Leu Leu Phe Pro Ser Met Ala Ser Met Ala Met His Val Ala Gln Pro  
20 25 30

Ala Val Val Leu Ala Ser Ser Arg Gly Ile Ala Ser Phe Val Cys Glu  
35 40 45

Tyr Ala Ser Pro Gly Lys Tyr Thr Glu Val Arg Val Thr Val Leu Arg  
50 55 60

Gln Ala Asp Ser Gln Val Thr Glu Val Cys Ala Ala Thr Tyr Met Met  
65 70 75 80

Gly Asn Glu Leu Thr Phe Leu Asp Asp Ser Ile Cys Thr Gly Thr Ser  
85 90 95

Ser Gly Asn Gln Val Asn Leu Thr Ile Gln Gly Leu Arg Ala Met Asp  
100 105 110

Thr Gly Leu Tyr Ile Cys Lys Val Glu Leu Met Tyr Pro Pro Pro Tyr  
115 120 125

Tyr Glu Gly Ile Gly Asn Gly Thr Gln Ile Tyr Val Ile Asp Pro Glu  
130 135 140

Pro Cys Pro Asp Ser Asp Gln Glu Pro Lys Ser Ser Asp Lys Thr His  
145 150 155 160

Thr Ser Pro Pro Ser Pro Ala Pro Glu Leu Leu Gly Gly Ser Ser Val  
165 170 175

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr  
180 185 190

Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu  
195 200 205

Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys  
210 215 220

Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser  
225 230 235 240

Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys  
245 250 255

Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile  
260 265 270

Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro  
275 280 285

Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu

290

295

300

Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn  
305 310 315 320

Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser  
325 330 335

Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg  
340 345 350

Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu  
355 360 365

His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys  
370 375 380



Exhibit 4

As used herein, "B7" refers to B7 family members including B7-1 (also known as CD80), B7-2 (also known as CD86) and B7-3 molecules that may recognize and bind CD28 and/or CTLA4.

5 As used herein "wild type CTLA4" has the amino acid sequence of naturally occurring, full length CTLA4 (U.S. Patent Nos. 5,434,131, 5,844,095, 5,851,795), or the extracellular domain thereof, which binds a B7, and/or interferes with a B7 from binding their ligands. In particular embodiments, the extracellular domain of wild type CTLA4 begins with methionine at position +1 and ends at aspartic acid at position +124, or the  
10 extracellular domain of wild type CTLA4 begins with alanine at position -1 and ends at aspartic acid at position +124. Wild type CTLA4 is a cell surface protein, having an N-terminal extracellular domain, a transmembrane domain, and a C-terminal cytoplasmic domain. The extracellular domain binds to target antigens, such as a B7. In a cell, the naturally occurring, wild type CTLA4 protein is translated as an immature polypeptide,  
15 which includes a signal peptide at the N-terminal end. The immature polypeptide undergoes post-translational processing, which includes cleavage and removal of the signal peptide to generate a CTLA4 cleavage product having a newly generated N-terminal end that differs from the N-terminal end in the immature form. One skilled in the art will appreciate that additional post-translational processing may occur, which  
20 removes one or more of the amino acids from the newly generated N-terminal end of the CTLA4 cleavage product. The mature form of the CTLA4 molecule includes the extracellular domain of CTLA4, or any portion thereof, which binds to B7.

"CTLA4Ig" is a soluble fusion protein comprising an extracellular domain of wild type CTLA4, or a portion thereof that binds a B7, joined to an Ig tail. A particular  
25 embodiment comprises the extracellular domain of wild type CTLA4 starting at methionine at position +1 and ending at aspartic acid at position +124; or starting at alanine at position -1 to aspartic acid at position +124; a junction amino acid residue glutamine at position +125; and an immunoglobulin portion encompassing glutamic acid at position +126 through lysine at position +357 (Figure 5).

and SEQ ID NO: 6

## Exhibit 4

| <u>Amino Acid</u> | <u>Symbol</u> | <u>One Letter Symbol</u> | <u>Codons</u>                |
|-------------------|---------------|--------------------------|------------------------------|
| Histidine         | His           | H                        | CAU, CAC                     |
| Isoleucine        | Ile           | I                        | AUU, AUC, AUA                |
| Lysine            | Lys           | K                        | AAA, AAG                     |
| Leucine           | Leu           | L                        | UUA, UUG, CUU, CUC, CUA, CUG |
| Methionine        | Met           | M                        | AUG                          |
| Asparagine        | Asn           | N                        | AAU, AAC                     |
| Proline           | Pro           | P                        | CCU, CCC, CCA, CCG           |
| Glutamine         | Gln           | Q                        | CAA, CAG                     |
| Arginine          | Arg           | R                        | CGU, CGC, CGA, CGG, AGA, AGG |
| Serine            | Ser           | S                        | UCU, UCC, UCA, UCG, AGU, AGC |
| Threonine         | Thr           | T                        | ACU, ACC, ACA, ACG           |
| Valine            | Val           | V                        | GUU, GUC, GUA, GUG           |
| Tryptophan        | Trp           | W                        | UGG                          |
| Tyrosine          | Tyr           | Y                        | UAU, UAC                     |

As used herein "the extracellular domain of CTLA4" is any portion of CTLA4 that recognizes and binds a B7. For example, an extracellular domain of CTLA4 comprises methionine at position +1 to aspartic acid at position +124 (Figure 5). Alternatively, an extracellular domain of CTLA4 comprises alanine at position -1 to aspartic acid at position +124 (Figure 5). The extracellular domain includes fragments or derivatives of CTLA4 that bind a B7.

an SEQ ID NO: 6 and SEQ ID NO: 6

As used herein, "lymphocyte" refers to mononuclear cells that mediate humoral- or cell-mediated immunity. Major subsets of lymphocytes include B and T cells.

As used herein, "immune system diseases" refer to autoimmune, immunoproliferative disorders and graft-related disorders including, but not limited to: graft-versus-host disease (GVHD) (e.g., such as may result from bone marrow transplantation, or in the induction of tolerance); immune disorders associated with graft transplantation rejection (e.g. chronic rejection, tissue or cell allo- or xenografts including solid organs, skin, islets,

disease being treated, the severity of the disease, a subject's health and response to the treatment with the agents. Accordingly, dosages of the agents can vary depending on each subject, agent and the mode of administration. For example, soluble CTLA4 molecules such as L104EA29YIg (included in Figure 6; as encoded by DNA deposited with ATCC accession number PTA-2104; and as described in U.S. Patent Application Serial Numbers 09/579,927, 60/287,576 and 60/214,065, incorporated by reference herein), may be administered in an amount between 0.1 to 20.0 mg/kg weight of a human subject/day, preferably between 0.5 to 10.0 mg/kg/day. and SEQ ID NOS: 8 and 9

- 10 Administration of the agents may be performed in many permissible ways including, but not limited to: injection (e.g. intravenous, intraperitoneal, intramuscular, etc.), oral administration, inhalation, topical contact, gene therapy, administration by a mechanical release device such as a pump, administration of slow release devices such as vesicles or capsules, or suppositories. Depending on the means of administration, the agents may be
- 15 compounded with pharmaceutically acceptable carriers for convenient application and effective use of the agents.

The pharmaceutical compositions also preferably include suitable carriers and adjuvants which include any material which when combined with the molecule of the invention (e.g., a soluble CTLA4 mutant molecule, such as, L104EA29Y or L104E) retains the molecule's activity and is non-reactive with the subject's immune system. Examples of suitable carriers and adjuvants include, but are not limited to, human serum albumin; ion exchangers; alumina; lecithin; buffer substances, such as phosphates; glycine; sorbic acid; potassium sorbate; and salts or electrolytes, such as protamine sulfate. Other examples include any of the standard pharmaceutical carriers such as a phosphate buffered saline solution; water; emulsions, such as oil/water emulsion; and various types of wetting agents. Other carriers may also include sterile solutions; tablets, including coated tablets and capsules. Typically such carriers contain excipients such as starch, milk, sugar, certain types of clay, gelatin, stearic acid or salts thereof, magnesium or calcium stearate, talc, vegetable fats or oils, gums, glycols, or other known excipients. Such carriers may also include flavor and color additives or other ingredients.

## Exhibit 4

A nucleotide sequence encoding CTLA4Ig was first generated as described *infra*, then a single-site mutant L104EIg was derived from the CTLA4Ig sequence and tested for binding kinetics for CD80 and/or CD86. The L104EIg nucleotide sequence was used as a template to generate the double-site mutant CTLA4 sequence, L104EA29YIg, which 5 was tested for binding kinetics for CD80 and/or CD86.

### Construction of CTLA4Ig

A genetic construct encoding CTLA4Ig comprising the extracellular domain of CTLA4 and 10 an IgCgamma1 domain was constructed as described in U.S. Patents 5,844,095 and 5,851,795, the contents of which are incorporated by reference herein. The extracellular domain of the CTLA4 gene was cloned by PCR using synthetic oligonucleotides corresponding to the published sequence as described by Dariavach et al. (72).

(SEQ ID NO:1)

15 Because a signal peptide for CTLA4 was not identified in the CTLA4 gene, the N-terminus of the predicted sequence of CTLA4 was fused to the signal peptide of oncostatin M (73) in two steps using overlapping oligonucleotides. For the first step, the oligonucleotide, CTCAGTCTGGTCCTTGCACTCCTGTTCCAAGCATGGCGAGCA TGGCAATGCACGTGGCCCAGCC (which encoded the C terminal 15 amino acids 20 from the oncostatin M signal peptide fused to the N terminal 7 amino acids of CTLA4) was used as forward primer, and TTTGGGCTCCTGATCAGAATCTGGGCACGGTTG

(SEQ ID NO:2) (encoding amino acid residues 119-125 of the amino acid sequence encoding CTLA4 receptor and containing a Bcl I restriction enzyme site) as reverse primer. The template for this step was cDNA synthesized from 1 micro g of total RNA from H38 cells (an

25 HTLV II infected T-cell leukemic cell line provided by Drs. Salahudin and Gallo, NCI, Bethesda, MD). A portion of the PCR product from the first step was reamplified, using an overlapping forward primer, encoding the N terminal portion of the oncostatin M signal peptide and containing a Hind III restriction endonuclease site, CTAGCCACTGAAGCTTCACCAATGGGTGTACTGCTCACACAGAGGACGCTGC

30 TCAGTCTGGTCCTTGCACTC and the same reverse primer. The product of the PCR reaction was digested with Hind III and Bcl I and ligated together with a Bcl 1/Xba I

(SEQ ID NO:3)

## Exhibit 4

cleaved cDNA fragment encoding the amino acid sequences corresponding to the hinge, CH2 and CH3 regions of IgG1 into the Hind III/Xba I cleaved expression vector, CDM8 or Hind III/Xba I cleaved expression vector  $\pi$ LN (also known as  $\pi$ LN).

*gamma*

5 DNA encoding the amino acid sequence corresponding to CTLA4Ig has been deposited with the ATCC under the Budapest Treaty on May 31, 1991, and has been accorded ATCC accession number 68629.

### CTLA4Ig Codon Based Mutagenesis to generate double mutants:

10 A mutagenesis and screening strategy was developed to identify mutant CTLA4Ig molecules that had slower rates of dissociation ("off" rates) from CD80 and/or CD86 molecules. Single-site mutant nucleotide sequences were generated using CTLA4Ig (U.S. Patent Numbers: 5,844,095; 5,851,795; and 5,885,796; ATCC Accession No. 68629) as a template. Mutagenic oligonucleotide PCR primers were designed for random 15 mutagenesis of a specific cDNA codon by allowing any base at positions 1 and 2 of the codon, but only guanine or thymine at position 3 (XXG/T; also known as NNG/T). In this manner, a specific codon encoding an amino acid could be randomly mutated to code for each of the 20 amino acids. In that regard, XXG/T mutagenesis yields 32 potential codons encoding each of the 20 amino acids. PCR products encoding mutations in close 20 proximity to -M97-G107 of CTLA4Ig (see Figure 5), were digested with SacI/XbaI and subcloned into similarly cut CTLA4Ig  $\pi$ LN expression vector. This method was used to generate the single-site CTLA4 mutant molecule L104EIg. *and SEQ ID NOS: 6 and 7*

25 For mutagenesis in proximity to S25-R33 of CTLA4Ig, a silent NheI restriction site was first introduced 5' to this loop, by PCR primer-directed mutagenesis. PCR products were digested with NheI/XbaI and subcloned into similarly cut CTLA4Ig or L104EIg expression vectors. This method was used to generate the double-site CTLA4 mutant molecule L104EA29YIg (Figure 6). In particular, the nucleic acid molecule encoding the single-site CTLA4 mutant molecule, L104EIg, was used as a template to generate the *and SEQ ID NOS: 8 and 9*

double-site CTLA4 mutant molecule, L104EA29YIg. The sequence of L104EA29YIg is shown in Figure 6 and includes an N-terminal leader sequence.

and SEQ ID NOS: 8 and 9

The following provides a description of the screening methods used to identify the single-  
5 and double-site mutant CTLA4 polypeptides, expressed from the constructs described  
*supra*, that exhibited a higher binding avidity for CD80 and CD86 antigens, compared to  
non-mutated CTLA4Ig molecules.

10 Current *in vitro* and *in vivo* studies indicate that CTLA4Ig by itself is unable to  
completely block the priming of antigen specific activated T cells. *In vitro* studies with  
CTLA4Ig and either monoclonal antibody specific for CD80 or CD86 measuring  
inhibition of T cell proliferation indicate that anti-CD80 monoclonal antibody did not  
augment CTLA4Ig inhibition. However, anti-CD86 monoclonal antibody did augment  
the inhibition, indicating that CTLA4Ig was not as effective at blocking CD86  
15 interactions. These data support earlier findings by Linsley et al. (74) showing inhibition  
of CD80-mediated cellular responses required approximately 100 fold lower CTLA4Ig  
concentrations than for CD86-mediated responses. Based on these findings, it was  
surmised that soluble CTLA4 mutant molecules having a higher avidity for CD86 than  
wild type CTLA4 should be better able to block the priming of antigen specific activated  
20 cells than CTLA4Ig.

To this end, the soluble CTLA4 mutant molecules described above were screened using a  
novel screening procedure to identify several mutations in the extracellular domain of  
CTLA4 that improve binding avidity for CD80 and CD86. This screening strategy  
25 provided an effective method to directly identify mutants with apparently slower "off"  
rates without the need for protein purification or quantitation since "off" rate  
determination is concentration independent as described by O'Shannessy et al (75).

30 COS cells were transfected with individual miniprep purified plasmid DNA and  
propagated for several days. Three day conditioned culture media was applied to  
BIAcore biosensor chips (Pharmacia Biotech AB, Uppsala, Sweden) coated with soluble

Flow Cytometry:

Murine mAb L307.4 (anti-CD80) was purchased from Becton Dickinson (San Jose, California) and IT2.2 (anti-B7-0 [also known as CD86]), from Pharmingen (San Diego, California). For immunostaining, CD80-positive and/or CD86-positive CHO cells were removed from their culture vessels by incubation in phosphate-buffered saline (PBS) containing 10mM EDTA. CHO cells (1-10 x 10<sup>5</sup>) were first incubated with mAbs or immunoglobulin fusion proteins in DMEM containing 10% fetal bovine serum (FBS), then washed and incubated with fluorescein isothiocyanate-conjugated goat anti-mouse or anti-human immunoglobulin second step reagents (Tago, Burlingame, California). Cells were given a final wash and analyzed on a FACScan (Becton Dickinson).

SDS-PAGE and Size Exclusion Chromatography

SDS-PAGE was performed on Tris/glycine 4-20% acrylamide gels (Novex, San Diego, CA). Analytical gels were stained with Coomassie Blue, and images of wet gels were obtained by digital scanning. CTLA4Ig (25 µg) and L104EA29YIg (25 µg) were analyzed by size exclusion chromatography using a TSK-GEL G300 SW<sub>XL</sub> column (7.8 x 300mm, Tosohas, Montgomeryville, PA) equilibrated in phosphate buffered saline containing 0.02% NAN<sub>3</sub> at a flow rate of 1.0 ml/min.

20 CTLA4X<sub>C120S</sub> and L104EA29YX<sub>C120S</sub>

Single chain CTLA4X<sub>C120S</sub> was prepared as previously described (Linsley et al., (1995) J. Biol. Chem., 270:15417-15424 (84)). Briefly, an oncostatin M CTLA4 (OMCTLA4) expression plasmid was used as a template, the forward primer, 25 GAGGTGATAAAGCTTCACCAATGGGTGTACTGCTCACACAG (SEQ ID No:4) was chosen to match sequences in the vector; and the reverse primer, GTGGTGTATTGGTCTAGATCAATCAGAATCTGGGCACGGTTC (SEQ ID No:5) corresponded to the last seven amino acids (i.e. amino acids 118-124) in the extracellular domain of CTLA4, and contained a restriction enzyme site, and a stop codon (TGA). 30 The reverse primer specified a C120S (cysteine to serine at position 120) mutation. In particular, the nucleotide sequence GCA (nucleotides 34-36) of the reverse primer shown